| Título: | Rash rates with EGFR inhibitors: meta-analysis |
| Autores: |
Mittmann, N.; HOPE Research Centre, Sunnybrook Health Sciences Centre Seung, S. J.; HOPE Research Centre, Sunnybrook Health Sciences Centre |
| Fecha: | 2011-04-04 |
| Publicador: | Multimed Inc. |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | Epidermal growth factor receptor inhibitors; meta-analysis; rash |
| Descripción: | IntroductionCurrently marketed epidermal growth factor receptor inhibitors (EGFRIs) have been associated with high rates of dermatologic toxicity.MethodsWe formally reviewed the literature at MEDLINE and EMBASE. Additional searches were conducted using Internet search engines. Studies were eligible if they were randomized controlled clinical trials of EGFRIs, specifically cetuximab and panitumumab, in which at least one arm consisted of a non-EGFRI treatment and rash safety data were reported. The random effects method was used to pool differences in incident rash rates. Results are summarized as differences in incident rash (EGFRI therapy rate minus the non-EGFRI therapy rate) with corresponding 95% confidence intervals (CIs) for all severity grades of rash and for grades 3 and 4 rash.Results Sixteen studies met the initial inclusion criteria of randomized controlled trials comparing EGFRI with non-EGFRI therapy. Seven publications that provided information on all severity grades of rash were found to have an overall difference in incident rash rate of 0.74 (95% CI: 0.68 to 0.81; p < 0.01). Thirteen studies that reported the incidence of grades 3 and 4 rash showed an overall difference in the incident rash rate of 0.12 (95% ci: 0.09 to 0.14; p < 0.01) between EGFRI and non-EGFRI therapy. Sensitivity analyses showed that the results were generally robust, but sensitive to small samples.ConclusionsResults quantify the difference in rash rates between EGFRI and non-EGFRI therapy |
| Idioma: | Inglés |
1 Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind por Sagar, Stephen,Dryden, Trish; Centre for Applied Research, Centennial College,Wong, Raimond K; McMaster University, Departments of Medicine and Oncology | 6 |
2 Chinese Medicine and Biomodulation in Cancer Patients (Part Two) por Sagar, Stephen M,Wong, Raimond K | 7 Cord stem-cell transplantation in Ontario: do we need a public bank? por Gassas, A.; the Hospital for Sick Children, Toronto |
3 Integrating Science and Human Values for Cancer Patient Care por Sutcliffe, Simon B.; BC Cancer Agency | 8 Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis por Szwajcer, D.; University of Manitoba,Czaykowski, P.; University of Manitoba,Turner, D.; CancerCare Manitoba |
4 Conservative Treatment of Invasive Bladder Cancer por Souhami, Luis; McGill University,Rene, Nicholas,Cury, Fabio Biagini | 9 Liver transplantation for symptomatic liver metastases of neuroendocrine tumours por Chan, G.; Hôpital Maisonneuve-Rosemont
Université de Montréal,Kocha, W.,Reid, R.,Taqi, A.,Wall, W.,Quan, D. |
5 A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital por Chin, S. N.,Wang, L.,Moore, M.,Sridhar, S. S.; University of Toronto | 10 What is the optimal management of dysphagia in metastatic esophageal cancer? por Cavallin, F.; Veneto Institute of Oncology,Scarpa, M.; Veneto Institute of Oncology,Cagol, M.; Veneto Institute of Oncology,Alfieri, R.; Veneto Institute of Oncology,Castoro, C.; Veneto Institute of Oncology |